| Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured aluminosilicate compounds. | |
| | |
MedLine Citation:
|
PMID: 19090562 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of this work was to assess the ability of aqueous suspensions of surface-modified nanostructured aluminosilicate (NSAS) compounds to reduce the intestinal absorption of cholesterol in a rat model. The rats were divided into 10 treatment groups which included several NSAS compounds at various doses, ezetimibe at 10 mg/kg, stigmastanol at 50 mg/kg, and normal saline. All compounds and controls were independently administered by oral gavage and then a mixture of [(3)H]cholesterol and cold cholesterol in 10% Intralipid(R) was immediately administered orally to the animals. Systemic blood was sampled and the concentration of cholesterol in plasma was determined by means of radioactivity. Protonation of NSAS using an ion-exchange column resulted in significant inhibition of cholesterol absorption relative to the control group (31.5% and 38.6% reduction in absorption of cholesterol for 50 and 100 mg/kg doses, respectively). Other surface-ion modifications of NSAS compounds did not show significant effect on intestinal cholesterol absorption. The inhibition of cholesterol absorption by ezetimibe was superior and by stigmastanol was equal to the effect of protonated NSAS in the doses investigated in this study. In conclusion, protonated NSAS material seems to inhibit significantly the intestinal absorption of dietary cholesterol in a rat model. |
| | |
Authors:
|
Pavel Gershkovich; Jerry Darlington; Olena Sivak; Panayiotis P Constantinides; Kishor M Wasan |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of pharmaceutical sciences Volume: 98 ISSN: 1520-6017 ISO Abbreviation: J Pharm Sci Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-06-02 Completed Date: 2009-08-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 2985195R Medline TA: J Pharm Sci Country: United States |
Other Details:
|
Languages: eng Pagination: 2390-400 Citation Subset: IM |
Affiliation:
|
Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada. pgershko@interchange.ubc.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aluminum Silicates
/
chemistry*,
pharmacology* Animals Anticholesteremic Agents / pharmacology Azetidines / pharmacology Cholesterol / blood, metabolism* Intestinal Absorption / drug effects* Male Nanostructures / chemistry Particle Size Protons Rats Rats, Sprague-Dawley Sitosterols / pharmacology Surface Properties Viscosity |
| Chemical | |
Reg. No./Substance:
|
0/Aluminum Silicates; 0/Anticholesteremic Agents; 0/Azetidines; 0/Protons; 0/Sitosterols; 163222-33-1/ezetimibe; 57-88-5/Cholesterol; 83-45-4/stigmastanol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Molecular genetics of ameloblast cell lineage.
Next Document: Molecular dynamics simulations of fluid methane properties using ab initio intermolecular interactio...